

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

### STA Edoxaban tosylate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final Appraisal Determination

(when no ACD was issued)

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No equalities issues were identified during scoping.
--

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No other equalities issues relevant to protected characteristic groups have been raised.
--

- |  |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

No equalities issues were identified by the Committee
---

- |  |
|--|
| 4. Do the recommendations make it more difficult in practice for a |
|--|

specific group to access the technology compared with other groups?  
If so, what are the barriers to, or difficulties with, access for the  
specific group?

No.

5. Is there potential for the recommendations to have an adverse impact  
on people with disabilities because of something that is a  
consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee  
could make to remove or alleviate barriers to, or difficulties with,  
access identified in questions 4 or 5, or otherwise fulfil NICE's  
obligations to promote equality?

No.

7. Have the Committee's considerations of equality issues been  
described in the final appraisal determination, and, if so, where?

No – no issues relevant to protected characteristic groups have been raised  
at any stage of the process.

**Approved by Programme Director (name):** Meindert  
Boysen.....

**Date:** 19<sup>th</sup> June 2015